found that CD8+ T cells from NSCLC and melanoma patients with musculoskeletal irAEs, when treated in vitro with tofacitinib, continued to secrete cytokines and display immune‐effector cell surface markers, inhibiting lung cancer progression. The gene discussed is CD8A; the disease is melanoma.